|
Welcome to the first installment of Conversations With Carevoyance, a new series dedicated to highlighting healthcare and MedTech vendors, thought leaders, and innovators. Today, we’re thrilled to share an interview with Gavin Doree, Vice President of Sales and Marketing at Exalenz Bioscience.
Founded in 2006, Exalenz is one of two commercially available 13C Urea Breath tests in the United States for the diagnosis and confirmation of eradication of Helicobacter pylori (H. pylori). Specializing in noninvasive modalities for different GI and liver function diagnostics, Exalenz Bioscience’s patented BreathID technology delivers immediate results with industry leading specificity and sensitivity.
0 Comments
|
Stay Up-to-Date
Archives
May 2019
Categories
All
|
RSS Feed
